Jean-Jacques Kiladjian is Professor of Clinical Pharmacology at Paris Diderot University, consultant Hematologist and head of the Clinical Investigation Center of the Saint Louis Hospital, Paris, France.
His research focuses on myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes with an interest in evaluating novel therapeutics and implementing clinical trials.
Professor Kiladjian is an active member of many societies including the European Hematology Association (EHA), where he is the chair of the Scientific Working Group on Myeloproliferative Neoplasms, the American Society of Hematology (ASH), as well as the European LeukemiaNet, where he is secretary of the working group on myeloproliferative neoplasms. He has also an active presence on his twitter, @jjkiladjian, where he shares updates in MPNs.
He was elected President of the French Intergroup of Myeloproliferative disorders (FIM group) in 2008.